Xenogen, Schering-Plough form target validation collaboration

By Elaine Rigoli

Tampa, Fla., Aug. 17 - Xenogen Biosciences, now Caliper Life Sciences, Inc., announced a target validation collaboration with Schering-Plough Corp. under which Xenogen will use its proprietary Serial Phenotyping Compression Technology (SPCT) to characterize high-value targets resulting from drug-discovery research conducted by the Schering-Plough Research Institute.

SPCT evaluates the physiological and behavioral impact of such high value targets by using a battery of more than 85 pharmacologically validated challenge or bioassays (measuring over 400 individual parameters), and covering most therapeutic areas, according to a company news release.

The recently signed phenotypic characterization agreement expands on a previous gene targeting agreement aimed at the creation of standard and conditional gene knockouts, both of which contribute to a fuller understanding of the biological effects associated with the deletion of a gene's function, the release said.

Financial terms of the deal were not disclosed.

Caliper (Xenogen) is a biotechnology company in Hopkinton, Mass.

Schering-Plough is a pharmaceutical company with headquarters in Kenilworth, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.